Interpace Prices 3.1M-Share Nasdaq Uplist Offering at $6.00-$7.00
IDXG sits 45% above its 52-week low of $3.85 on light trading volume (0.2× avg).
Summary
Interpace launched a firm-commitment underwritten offering of 3.1 million shares at $6.00-$7.00, targeting about $17.9 million net to fund operations and support its Nasdaq uplisting. The deal only closes if Nasdaq approves the listing, and it dilutes existing holders by roughly a third.
Key Events · Financing and Capital Events · IDXG
-
3.1M-Share Underwritten Offering Launched
A firm-commitment offering of 3,100,000 shares at an estimated $6.00-$7.00 per share, plus a 465,000-share over-allotment option, led by Lake Street Capital Markets with Laidlaw & Company (UK).
-
About $17.9M Net Proceeds at Midpoint
At the $6.50 midpoint, estimated net proceeds come to approximately $17.9 million ($20.8 million with the over-allotment), after a 6.0% underwriting discount ($0.39 per share) and roughly $1.0 million of offering expenses.
-
Roughly One-Third Dilution to Existing Holders
The 3,100,000 new shares compare against 5,901,962 shares outstanding as of October 28, 2026; at the $6.50 midpoint, new investors absorb $2.03 per share of immediate net tangible book value dilution.
-
Closing Contingent on Nasdaq Approval
The offering will not be consummated unless Nasdaq conditionally approves the listing of the common stock, which currently trades on the OTCID; the 1-for-5 reverse split in August 2026 was done to meet Nasdaq's minimum bid price.
Analysis · IDXG · Industrial Applications And Services
Interpace is selling 3.1 million new shares at $6.00-$7.00 to fund operations and satisfy Nasdaq's listing standards — and the whole deal hinges on that approval, since if Nasdaq says no, the offering does not close. At the $6.50 midpoint the company nets about $17.9 million, roughly seven times the $2.7 million of cash it held at June 30, 2026, enough to fund the pancreatic and Barrett's esophagus test development programs that currently have no revenue. The cost is dilution: 3.1 million shares against 5.9 million outstanding, so existing holders give up roughly a third of the company, and new buyers absorb $2.03 per share of immediate net tangible book value dilution. The $6.00-$7.00 range sits above the $5.72 last reported OTCID sale price on October 29, 2026, but the filing itself warns the final price may be set at a discount to market.
How filings like this one have moved
In the 30 days to Oct 30, 2026, 38.3% of the 891 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IDXG was trading at $5.59 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $33M. The 52-week trading range was $3.85 to $12.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.